In the treatment landscape of idiopathic pulmonary fibrosis, pirfenidone is one of the few drugs that can slow disease progression. Pirespa powder is chemically 5-methyl-1-phenyl-2-(1H)-pyridone, a small-molecule antifibrotic drug. As a multi-target antifibrotic agent, pirfenidone exerts its antifibrotic effects through multiple pathways, including inhibiting the production and activity of transforming growth factor-β (TGF-β), reducing collagen synthesis, and downregulating inflammatory mediators, although its exact molecular mechanism is not yet fully elucidated.
🧬 Phenylidene pyridone stabilizes the drug's molecular skeleton
Pirespa powder has the complete molecular formula C₁₂H₁₁NO and a relative molecular mass of 185.22. Its core is a rigid heterocyclic structure of 5-methyl-1-phenyl-2-pyridone, lacking chiral carbon atoms and free from stereoisomeric impurities that could interfere with cellular fibrosis detection data. The conjugated planar structure of the pyridine heterocycle and phenyl group ensures the molecular's storage stability. Ordinary pyridone molecules without phenyl modification exhibit polarity imbalance and are easily degraded by intracellular oxidases, failing to sustainably act on fibroblast signaling pathways. In contrast, Pirespa powder forms a conjugated, hydrophobic plane with the phenyl ring. Even after 30 months of storage in a sealed, dry container protected from light at 2-8°C, it maintains its intact closed-ring heterocyclic configuration. Long-term co-incubation experiments with lung fibroblasts and renal tubulointerstitial cells do not show methyl hydrolysis or breakage, thus providing sustained and stable blocking of fibrosis signal transduction.
The central pyridone five-membered heterocycle is the core functional region binding to the TGF-β transcriptional regulatory region. The carbonyl group within the ring forms a hydrogen bond with the nitrogen atom, allowing it to embed into the promoter cavity of collagen-promoting genes within the fibroblast nucleus, suppressing the transcriptional expression of type I and II procollagen. Derivatives lacking the pyridone carbonyl structure cannot anchor gene regulatory fragments, only weakly inhibiting inflammatory factors, and exhibiting almost complete loss of anti-fibrotic activity. The intact pyridone heterocycle is the core structural support for this product's blocking of collagen deposition.
The side-chain methyl group and the terminal phenyl group synergistically regulate the lipid-water partition ratio of the molecule. The methyl group enhances the heterocycle's lipid solubility, while the phenyl group constructs a hydrophobic binding plane. This dual modification allows the molecule to smoothly penetrate the lipid layer of alveolar epithelium and renal tubular interstitial cell membranes, rapidly reaching the intracellular space to exert its regulatory effect. Highly polar small molecules struggle to penetrate the thickened fibrotic tissue barrier, and strongly hydrophobic raw materials tend to precipitate and aggregate in the culture medium.
Pirespa powder balances tissue penetration and solvent dispersibility, making it suitable for high-throughput fibroblast fibrosis screening and large-scale three-dimensional lung organoid simultaneous culture experiments.
The entire molecule exhibits no broad-spectrum cytotoxicity, specifically targeting fibrotic-activated fibroblasts. It does not significantly interfere with the basal metabolic pathways of normal resting epithelial cells and immune cells, distinguishing diseased scar cells from healthy tissue cells at the molecular level and reducing interference from non-specific pathways. Removing any phenyl or methyl modification group significantly reduces the molecule's affinity for the TGF-β pathway, resulting in a marked decrease in its inhibitory effect on organ fibrosis.
⚙️ Triple pathways synergistically block the cascade reaction of organ fibrosis
In healthy individuals, fibroblasts in the interstitial tissue of organs remain in a resting state. The secretion of pro-fibrotic growth factors such as TGF-β, PDGF, and bFGF is maintained at extremely low levels. Type I and II collagen synthesis and degradation are in dynamic equilibrium. The interstitial tissue is soft and free of scar accumulation. The basal release of pro-inflammatory factors such as TNF-α and IL-1β is weak, and they do not induce abnormal proliferation of interstitial cells or tissue sclerosis. Gene transcription in normal mammalian epithelial and parenchymal cells is not interfered with by exogenous pyridone molecules, and cell proliferation, metabolism, and repair maintain a stable homeostasis.
When the lungs, kidneys, and liver experience chronic inflammation, toxin stimulation, and repeated damage, tissue macrophages and interstitial cells release large amounts of TGF-β1, a core pro-fibrotic factor. This drives resting fibroblasts to transform into highly secretory myofibroblasts, continuously and excessively synthesizing collagen fibers and fibronectin, leading to the accumulation of large amounts of extracellular matrix and the formation of sclerotic scars. Simultaneously, the continuous outbreak of inflammatory factors and the accumulation of reactive oxygen species exacerbate cell damage, forming a vicious cycle of "inflammation - oxidative stress - collagen deposition." Organs gradually lose their normal elasticity, and respiratory, filtration, and metabolic functions continuously decline. Conventional single anti-inflammatory agents only temporarily reduce inflammatory factors and cannot block the continuous production of collagen, resulting in the irreversible progression of fibrotic lesions.
Pirespa powder, after penetrating diseased interstitial cells, utilizes the conjugated planar structure of phenylpyridinone:
- Its first action directly inhibits the transcription and secretion of TGF-β1, PDGF, and bFGF in macrophages and interstitial cells, cutting off the release of pro-fibrotic signals at the source, blocking the activation and differentiation process of fibroblasts, significantly reducing the number of myofibroblasts, and decreasing the supply of templates for collagen and fibronectin synthesis. The second pathway simultaneously downregulates the NF-κB inflammatory signaling pathway, inhibiting the release of pro-inflammatory factors such as TNF-α, IL-1β, IL-6, and MCP-1, while upregulating the expression of the anti-inflammatory factor IL-10.
- This balances the Th1/Th2 immune response, alleviates persistent low-grade inflammation at the lesion site, eliminates upstream factors that continuously stimulate fibrosis, and prevents repeated inflammation-induced collagen accumulation.
- The third pathway exerts endogenous antioxidant activity, scavenging excess intracellular reactive oxygen species, reducing oxidative stress damage to organ parenchymal cells, decreasing oxidation-mediated collagen cross-linking and solidification, and preventing the hardening of loose collagen fibers into permanent scar tissue. The simultaneous action of these three pathways achieves a complete anti-fibrotic chain: controlling signaling at the source, suppressing inflammation in the middle, and inhibiting collagen deposition at the end. This differs from ordinary small-molecule raw materials that only block inflammation or collagen synthesis individually.
Pirespa powder targets only the mesenchymal fibroblast pathway activated by fibrotic lesions and does not significantly interfere with the gene expression and metabolic cycle of normal tissue cells. Broad-spectrum anti-fibrotic agents indiscriminately suppress cell growth factors throughout the body. Experimental systems are contaminated with a large number of irrelevant interfering signals such as apoptosis and metabolic disorders of normal organs. Pirespa powder has specific target stratification, which can accurately lock the single variable of "TGF-β-mediated organ fibrosis inhibition" in scientific research experiments, greatly improving the accuracy and persuasiveness of experimental conclusions related to lung, kidney, and liver fibrosis.
🧫 Full coverage of fibrous scientific research application scenarios
Pirespa powder is a standard positive control material for in vitro fibrosis mechanism studies of idiopathic pulmonary fibrosis (IPF), primarily used for constructing primary human lung fibroblasts and three-dimensional alveolar organoid fibrosis models. The core pathology of IPF is TGF-β-driven excessive collagen deposition. Researchers utilize the triple anti-fibrotic activity of Pirespa powder to conduct quantitative collagen assays, detect myofibroblast markers, and perform ELISA quantification of inflammatory factors, establishing a standardized efficacy evaluation system for pulmonary fibrosis drugs. This allows for horizontal comparisons of the organ scar inhibition effects of various novel heterocyclic anti-fibrotic small molecules and natural extracts.
Pirespa powder is widely used in organ pharmacological studies related to renal interstitial fibrosis and liver fibrosis, and is suitable for co-culture models of oxidative damage in renal tubulointerstitial cells and hepatic stellate cells. Chronic kidney disease and viral hepatitis cause long-term damage that continuously induces interstitial collagen accumulation. Pirespa powder can simultaneously inhibit the release of pro-fibrotic factors and inflammation, delaying the progression of organ sclerosis. Researchers have identified common regulatory pathways of fibrosis in multiple organs and screened broad-spectrum organ-protective active substances, providing a stable experimental carrier for the development of oral drugs for liver and kidney fibrosis.
It has irreplaceable value in the research of cardiac remodeling and skin scar hyperplasia, and is used to construct in vitro models of myocardial fibroblast and dermal fibroblast injury. Myocardial fibrosis and hypertrophic scars are common after myocardial infarction and trauma surgery. Pirespa powder can reduce excessive collagen fiber proliferation and is often used in research on postoperative organ remodeling and skin scar repair, expanding the development direction of broad-spectrum anti-fibrotic agents for multiple organs.
Globally, the development of novel pyridone anti-fibrotic lead molecules uses Pirespa powder as a standardized efficacy reference. Various phenylpyridine ring-modified derivatives, organ-targeted modified small molecules, and long-acting sustained-release antifibrotic prodrugs require cross-sectional comparison of core indicators such as TGF-β inhibition efficiency, reduction in collagen deposition, anti-inflammatory and antioxidant capacity, and non-specific toxicity to organ parenchymal cells. Stable and consistent triple pathway regulatory activity, low interference from healthy cells, and highly reproducible cell assay data make it a universal standard for high-throughput initial screening of new antifibrotic drugs, structure-activity relationship analysis of pyridine heterocycles, and iterative optimization of molecular structures.
🔬 Iterative optimization direction of phenylpyridinone molecules
Site-specific modification of the pyridine ring side chain is currently the mainstream approach for optimizing Pirespa powder molecules, with a focus on modifying the methyl group at position 5 and the phenyl group at position 1. The original molecule diffuses uniformly throughout the body, but its concentration in lung and kidney lesions is limited, requiring moderate concentrations to inhibit interstitial fibrosis. By grafting short peptides with alveolar epithelial and renal tubular affinity onto the phenyl terminus, the modified derivative can be directionally enriched in the interstitial region of diseased organs. Lower molar doses can block TGF-β fibrosis signaling, reducing trace drug exposure in peripheral healthy organ cells, and making it suitable for developing low-dose, long-acting organ fibrosis intervention models.
Microenvironment-responsive prodrug modification of fibrotic lesions is a popular optimization route in recent years, addressing the issue of weak basal cellular metabolic interference caused by indiscriminate penetration of molecules throughout the body. The research team has incorporated a cleavable masking group at the carbonyl site of the pyridone group into the acidic microenvironment of fibrotic lesions, constructing a specific activating prodrug for the interstitial lesion. The modified prodrug exhibits no TGF-β pathway inhibitory activity in neutral, healthy organ cells, thus not interfering with normal collagen metabolism. Only upon entering the acidic lesion region of inflammatory fibrosis does the masking group break down, releasing the active pirfenidone core, precisely targeting and blocking interstitial collagen deposition. This further enhances the molecular organ-specific targeting, aligning with the trend of low-toxicity, broad-spectrum anti-fibrotic active pharmaceutical ingredients (APIs).
Multi-pathway hybrid molecule splicing broadens the boundaries of pharmacological action, overcoming the limitations of a single pyridone backbone that only regulates fibrosis, inflammation, and oxidative stress. Chronic organ fibrosis is often accompanied by multiple problems such as apoptosis and microvascular damage; simply inhibiting collagen deposition cannot completely repair organ structural damage. Researchers covalently spliced the phenylpyridone core backbone of this product with anti-apoptotic and vascular repair active fragments to create a multi-functional hybrid small molecule. This simultaneously achieves four effects: blocking pro-fibrotic factors, reducing lesion inflammation, scavenging free radicals, and protecting organ parenchymal cells. This overcomes the functional limitations of single-target anti-fibrotic APIs and provides a new approach for designing complex multi-organ protective lead molecules.
Pyridine ring substitution fine-tunes the TGF-β pathway inhibition bias, adapting to the personalized needs of different organ fibrosis research scenarios. The original Pirespa powder has a balanced inhibitory effect on lung and kidney fibrosis, suitable for general chronic interstitial injury models; by adjusting the phenyl substituent group and the methyl carbon chain length, the binding affinity of the molecule to lung fibroblasts and hepatic stellate cells can be precisely adjusted. The highly selective lung derivative is suitable for idiopathic pulmonary fibrosis-specific experiments, while the balanced derivative is suitable for multi-organ fibrosis models involving the liver and kidneys, enabling precise subtyping of organ fibrosis research.
Conclusion
Pirespa powder is the first small-molecule antifibrotic drug approved for the treatment of idiopathic pulmonary fibrosis. Its pyridone skeleton endows it with multi-target pharmacological activity. By inhibiting pro-fibrotic growth factors such as TGF-β, blocking MRTF transcription factor signaling, and regulating inflammatory responses, pirfenidone has demonstrated clear clinical benefits in delaying the decline of lung function.
Xi'an Faithful BioTech Co., Ltd. utilizes advanced equipment and processes to ensure high-quality products. Our Pirespa powder meets international pharmaceutical standards. Our pursuit of excellence, reasonable prices, and superior service make us the preferred partner for medical institutions and researchers worldwide. If you require Pirespa powder research or production, please contact our technical team at allen@faithfulbio.com.
References
- Therapeutic Target Database. (n.d.). Pirfenidone Drug Information (D02WCI).
- Therapeutic Target Database. (n.d.). Pirfenidone API Details (D00536).
- NCATS Inxight Drugs. (n.d.). Pirfenidone (D7NLD2JX7U).
- Acta Crystallographica Section E. (2019). Crystal structure of pirfenidone. 75, 984-986.
- Deutsches Zentrum für Lungenforschung. (2017). Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors. FASEB Journal, 31(5), 1916-1928.
- European Respiratory Journal. (2023). Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone. 61(4), 2200604.